Will Morton[email protected]RSNA 2024MRI links long-COVID brain fog to lung functionMRI shows that lower pulmonary gas exchange in the lungs of long-COVID patients may be associated with cognitive symptoms.November 26, 2024Molecular ImagingPET scan times can be reduced in Alzheimer’s patientsF-18 florbetaben PET scans for diagnosing Alzheimer’s disease can be reduced from 20 minutes to five minutes without losing accuracy.November 25, 2024RSNA 2024Thyroid medication linked to bone lossLevothyroxine – a common medication taken for hypothyroidism – may be associated over time with bone loss.November 25, 2024Practice ManagementDoes AI contribute to burnout for radiologists?Frequent AI use is associated with an increased risk of radiologist burnout, particularly among those with high workloads and low AI acceptance.November 22, 2024AILLMs decrease in accuracy over time on radiology examsLarge language models (LLMs) demonstrate high accuracy on radiology exams, yet decrease in accuracy over time.November 21, 20242024 Molecular Imaging PreviewRoad to RSNA 2024: Molecular Imaging PreviewTheranostics could be cited for speeding in this year’s Road to RSNA. It's only been a few years since a dedicated track in nuclear medicine and molecular imaging was established at the meeting, and the practice already dominates it.November 21, 20242024 Molecular Imaging PreviewFAPI-PET/CT superior to FDG-PET/CT in liver cancer patientsGa-68 FAPI-PET/CT imaging appears superior to FDG-PET/CT for assessing hepatocellular carcinomas. In a large prospective trial, the approach was more accurate – enough so that it could possibly replace FDG-PET/CT in the future.November 21, 20242024 Molecular Imaging PreviewFAPI-PET/CT improves detection of primary and metastatic breast cancerGa-68 FAPI-PET/CT significantly enhances the detection rate and staging of primary and metastatic breast cancer, demonstrating superior sensitivity and specificity compared with F-18 FDG-PET/CT.November 21, 20242024 Molecular Imaging PreviewTheranostics cost-effective in men with mCRPCUsing theranostic radionuclides such as Ra-223 or Lu-177 to treat men with metastatic castration-resistant prostate cancer (mCRPC) is more cost-effective in the long term than traditional chemotherapy and radiotherapy, suggests a study in this session.November 21, 20242024 Molecular Imaging PreviewTreatment-related factors enhance PSMA expressionCertain prostate cancer features on PSMA-PET may be useful in selecting candidates who are more likely to respond to Lu-177 PSMA-617, according to a presentation in this session.November 21, 2024Previous PagePage 11 of 50Next PageTop StoriesDigital X-RayChest x-rays reveal atherosclerosis in patients undergoing amputationsLower limb amputation is an increasingly common major complication of advanced peripheral arterial disease and diabetes mellitus.MRI3D MRI technique helps plan treatment for pediatric heart conditionsWomens ImagingCould AI scoring help with managing DCIS?CTClinicians, beware: CT diagnostic accuracy varies by adnexal lesion typePractice ManagementRadiology coding update for 2026